Abstract
Inhibitors of the renin-angiotensin system (RAS) are cornerstones of supportive therapy in patients with IgA nephropathy (IgAN). In the randomized STOP-IgAN trial we observed that the addition of immunosuppressive therapy to optimized supportive care did not significantly improve renal outcomes over the 3-year study phase as compared to supportive measures alone. Here we analyzed the effects of single versus dual RAS blockade during the 6-month run-in phase that preceded the randomized study phase on renal endpoints.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
